NEW YORK ( TheStreet) -- Shares of Skystar Bio-Pharmaceutical Company (Nasdaq: SKBI) have taken a tremendous swing upward. The stock is trading at $3 as of 3:56 p.m. ET, 35.1% above Friday's closing price of $2.22. Volume is at 64,862, 2.3 times the daily average of 28,700. Skystar has a market cap of $16.8 million and is part of the health care sector and drugs industry. Shares are down 77.2% year to date as of the close of trading on Friday. Skystar Bio-Pharmaceutical Company engages in the research, development, production, marketing, and sale of veterinary healthcare and medical care products in the People's Republic of China. The company has a P/E ratio of 1.2, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Skystar as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and a generally disappointing performance in the stock itself. You can view the full Skystar Ratings Report. See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center. Interested in other stocks that are soaring? Get free SMS text alerts sent to you when the action happens by texting SOAR to 95370 or select from multiple alert options.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Markets
S&P 500 Support Holds, but a Third Test Would Likely Be a Different Story
While the bears have been unsuccessful so far in breaking support, the bulls have been equally lackluster in generating upside momentum.
Beyond Pricey? Our Reporters Try the Beyond Meat Burger, Talk Business Model
Is Beyond Meat's burger enough to convince investors to invest in the company? TheStreet conducted a taste test to see what the hype is about.
I've Got Just the Right Trade for This 3-Day Weekend
In any other administration I'd avoid the idea, but this administration and this president love to get on social media and make a splash.
Add Foot Locker to the Latest List of Retail Casualties
There's little in the report or technical picture that makes me want to rush into FL.
Beijing Pleads for 'Positive Energy' Over Terrible Extradition Law in Hong Kong
The central government's office in Hong Kong has ordered the international media to skew their coverage to the 'positive' side on HK's proposed extradition law to China.